Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mazindol is chemically unrelated to the phenethylamines and has not shown the side-effects or abuse potential of the amphetamine anorectics. To further define its potential for causing weight loss, a six-week double-blind placebo controlled study was undertaken in four centres. A common protocol was used except in one centre, behavioural modification also was employed, whereas in the other centres, no additional measures were used to cause weight loss. Two hundred and forty-five obese patients were assigned randomly to two mazindol groups and one placebo group in each centre. Ninety-eight and forty patients receiving mazindol and placebo respectively completed the protocol. The conclusions were: (a) no significant clinical or laboratory abnormalities occurred from mazindol therapy, (b) the placebo therapy patients did not lose weight without behavioural modification, (c) the placebo therapy group had a higher drop-out rate compared to the mazindol therapy group attributable to the patients' dissatisfaction with failure to lose weight, (d) mazindol therapy without behavioural modification and behavioural modification alone both resulted in a statistically significant mean weight loss of 1 pound/patient/week and (e) mazindol plus behavioural modification resulted in a greater mean weight loss of 1/2 pound/patient/week than with behavioural modification alone. Hence, mazindol is of value in the initial therapy of obesity.
 ...
PMID:A multicentre study comparing mazindol and placebo in obese patients. 32 96

Mazindol, diethylpropion, and a placebo were compared with behavioral therapy for effectiveness in producing weight reduction in an outpatient obesity clinic. Each method was also compared in cost and harmful side effects. The patients were recruited from the middle and lower socioeconomic groups. Of the 120 patients beginning treatment, only 33 completed the entire 14-week study. There was no statistically significant difference in the weight loss among the treatment groups. The program of behavioral therapy was administered by a dietitian who as experienced in the techniques of behavior modification; the drug treatment groups were seen by physicians. We conclude that behavioral therapy may be the treatment of choice in an outpatient obese population since it requires little physician time, is less expensive, and avoids the side effects of anorectic drugs.
 ...
PMID:Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs. 41 15

The treatment of obesity is one of the major measures available today in the field of preventive medicine. In particular, the coronary epidemic of Western civilisation would be halted, and most cases of maturity-onset diabetes prevented, if obesity were to be treated effectively. Anorectic drugs act mainly on the satiety centre in the hypothalamus to produce anorexia. They also have various metabolic effects involving fat and carbohydrate metabolism, but many of these may be secondary to loss of weight. Most of the drugs are related directly or indirectly to amphetamine and in addition act by increasing general physical activity. Anorectic drugs tend to lose their effect after some months, and part of this reduction in effect may be due to chemical alterations produced by the drugs in the brain. All the drugs, with the exception of fenfluramine, have a stimulant effect on the central nervous system in some individuals, resulting in restlessness and nervousness, irritability and insomnia. Fenfluramine commonly produces drowsiness in normal doses, but has stimulant effects with overdosage. Dexamphetamine, phenmetrazine and benzphetamine all tend to cause euphoria and the risk of addiction is therefore considerable. Euphoria occasionally occurs with diethylpropion, phentermine and chlorphentermine, but to a much lesser extent. Side-effects also occur due to sympathetic stimulation and gastro-intestinal irritation. These side-effects may cause some individuals to stop taking the drug, but are never serious or dangerous. Drug interactions may occur with monoamine oxidase inhibitors and to a clinically unimportant extent, with antihypertensive drugs. The anorectic drugs have a very definite part to play in the treatment of obesity, mainly for those individuals who have altered their eating habits but have come to a plateau of weight which they find difficult to get below. The drugs are best given in a long-acting form and can safely be continued as long as weight loss persists, provided that the clinician exercises careful supervision. Dexamphetamine, phenmetrazine and benzphetamine should rarely be used because of the danger of addiction, and chlorphentermine is potentially hazardous for long-term use. Diethylpropion emerges as the drug of first choice, as fenfluramine has a tendency to cause depression and has a higher incidence of side-effects. Fenfluramine is mainly useful for people who are especially tense and for obese maturity-onset diabetics who have been unable to lose weight with the biguanides. Mazindol and phentermine appear to be useful as alternative drugs.
 ...
PMID:Anorectic drugs: use in general practice. 78 35

Pathologically increased apetite is the most tormenting symptom of overweight conditions and therefore, along with dietetic treatment which plays an essential role, it is most expedient to resort to anorectic drugs also. Recently, the Sanorex preparation (Mazindol, Teronak, AN 448 degrees--imidazo-isoindole derivative having a tricyclic structure) is ever more extensively used. The action of the drug is studied in a series of 32 obesity individuals under sanatorial conditions and normocaloric diet, over a period of twenty seven days. The new preparation Sanorex which causes aversion to food, given in small doses, accounts for prompt and reliable control of the apetite--9590 kg reduction, 0,362 kg mean daily weight loss (p less than 0,05), and equal intensity of weight loss in either of the sexes (p less than 0,01). Side effects such as dryness in the mouth, very strong and moderate thurst, insomnia, superficial sleep, headache, elevated excitability, tachycardia, general feebleness are transitory, subside within two weeks, and are tolerated comparatively well by the patients included in the series. Sanorex administration may be recommended provided due consideration is given to the usual limitations implied by the continuous use of new drugs.
 ...
PMID:[Treatment of obesity with the anoretic Sanorex]. 80 32

In a single blind study 25 out patients with exogenous obesity were treated for 6 weeks with Mazindol (2 mg one hour before lunch). The active treatment period was followed by a placebo period of 4 weeks. 9 out of 25 patients (group I) were asked to stick to a diet of 1000 cal daily for 14 days before entering the active treatment period. The rest of the patients (group II) were asked to start with this diet when entering the treatment period. There was practically no weight reduction during the initial 2 weeks on diet alone in group I. In both groups on Mazindol there was a significant weight reduction beginning after one week with a maximum weight loss of 4,1 and 5,1 kg respectively at the end of the active treatment period (2p less than 0,001). After the first week of the following placebo period there was an increase in weight in both groups (2p less than 0,01). During both treatment periods no changes in clinical (including) ergometric investigations) and laboratory findings were observed. However from these results no conclusions can be drawn regarding cardiopulmonary tolerance and abuse potential. In a few cases mild side effects related to the CNS have been found.
 ...
PMID:[Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)]. 99 40

The effectiveness and tolerance of a non-amphetaminic anorexiant drug has been evaluated in a short-term and in a long-term clinical trial in simple obesity and in refractory obesity. In the short-term 'crossover' trial, a more evident effectiveness and tolerance result when the anorexiant is given in a late phase of treatment. The association of an anorexiant drug with the hypocaloric diet was seen to be effective in the treatment of so-called refractory obesity. In the evaluation of the long-term treatment it is seen that weight loss is greater and remains so farr longer periods in patients receiving anorexiant, as compared to controls. This is related to a better maintenance of a restricted calorie regimen. Mazindol did not affect the improvement of glucose tolerance and insulin secretion which follows the weight reduction.
 ...
PMID:Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. 102 32

After a brief introductory discussion of methods generally used in the treatment of overweight (dieting; fasting; behavioral therapy; physical activity), the pharmacology of anorexigenic drugs and the considerations governing their clinical use and indications are discussed. All currently available anorexigens exert their action through nor-adrenergic stimulation at receptor sites located in the hypothalamus (amphetamine and ephedrine derivatives) or in the limbic system (Mazindol). In view of the CNS-stimulatory effect of these agents, drug addiction must be considered a potential hazard of their prolonged use. Since any drug treatment of obesity interferes with the patient's motivation to subject himself to the prolonged and possibly life-long changes in his eating habits and exertional behavior which are mandatory for the achievement of long-term therapeutic success, the use of drugs is rarely indicated in the treatment of obesity and should remain the exception. In view of their additional potential to induce drug addiction, this is particularly true of appetite suppressants.
 ...
PMID:[Mode of action and indication for appetite depressants in the treatment of obesity]. 112 73

The Japanese Mazindol study group investigated the action of an anorexiant, mazindol, and found that it reduced food intake by directly suppressing neurons in the lateral hypothalamus, inhibited gastric acid secretion, increased motor activity, decreased glucose absorption, and inhibited insulin secretion. It thus appears that the main effect of mazindol is to decrease food intake through suppressing feeding centers in the hypothalamus. A multicenter open study of mazindol in Japan revealed that loss of body weight and relative body weight in 14 wk were 4.6 kg and 9.2%, respectively, with suppression of appetite in the majority of obese patients. A multicenter double-blind study demonstrated that mazindol was superior to the placebo in the treatment of simple obesity. We also suggest that mazindol is effective in the maintenance of reduced body weight after obesity therapy and in the treatment of obesity-related diseases such as diabetes, hypertension, or hyperlipidemia.
 ...
PMID:Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. 172 34

The present experiments were carried out to elucidate the effect of mazindol feeding on obese mice made by gold-thioglucose injection. Mazindol was added to the diet at the level of 0.5, 2, 10 mg/kg body weight. It was found that oral administration of mazindol reduced the body weight gain and perimetrial adipose tissue weights increased in GTG-obese mice. Decreased adipose tissue weights were correlated with the decreased level of size and volume of fat cells. Basal lipolytic activity and adrenaline-induced lipolysis were also significantly decreased in mazindol groups as compared to those in GTG-obese mice that were not administered mazindol. These results indicate that the weight reduction induced by mazindol administration might not be due to increase in fat mobilization. The increased level of liver and serum lipid induced by GTG-obesity was also found to be improved by mazindol. Scanning electron micrographs indicated that the villous width of the small intestine were significantly smaller in the mazindol group that those in the GTG-obese group. Sucrase and esterase activities of the small intestine were also decreased by mazindol feeding as compared to those in the GTG-obese mice. based on these results mechanisms of action of mazindol were discussed.
 ...
PMID:[Effect of mazindol on obesity induced by administration of gold thioglucose]. 643 Jul 60

Biochemical and morphological studies were made on the role of mazindol in treatment of obesity in mice induced by gold thioglucose (GTG) injection. Mazindol was added to the diet at a level of 10 mg/kg body weight and then all animals were fed on a constantly restricted diet of 60 percent of the level of ad lib, food intake for 10 weeks. The following results were obtained: (1) The body weight and Lee's index were significantly increased by GTG injection and these increases in the GTG-obese group were reduced by oral mazindol. (2) The levels of triglyceride and cholesterol in the liver were much higher in the GTG-obese group than in the lean group, and were significantly less in the mazindol-treated group than in the GTG-obese group. (3) The levels of serum triglyceride and immunoreactive insulin were significantly higher in the GTG group than in the lean group and the increase in the GTG-treated animals was reduced by oral mazindol. (4) The size of fat cells and basal lipolytic activity in parametrial adipose tissue were greater in the GTG-obese group than in the lean group and were significantly reduced by mazindol treatment. (5) Disaccharidase activities in the small intestinal mucosa and the absorptive surface area of the mucosa were significantly greater in the GTG-obese group than in the lean group and were increased significantly less in the mazindol-treated group.
 ...
PMID:Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection. 644 12


1 2 Next >>